| Control | None | SHSSTc | SHSST | Silymarin |
---|
CCl4 | - | + | + | + | + |
---|
AST | 28.0 ± 2.5 | 42.9 ± 9.7*** | 25.9 ± 5.1## | 38.6 ± 11.6 | 35.1 ± 3.9 |
ALT | 27 ± 14 | 195 ± 20*** | 93 ± 15### | 116 ± 19## | 124 ± 25## |
TC | 50 ± 15 | 57 ± 14 | 50 ± 15 | 56 ± 17 | 50 ± 18 |
TG | 45 ± 20 | 54 ± 19 | 46 ± 43 | 47 ± 13 | 46 ± 13 |
CK | 483 ± 56 | 1399 ± 147*** | 998 ± 63# | 1137 ± 85 | 1024 ± 72# |
BUN | 29 ± 7 | 35 ± 7 | 31 ± 6 | 33 ± 7 | 32 ± 7 |
- All plasma samples (n = 6) were prepared from control group, CCl4-induced acute hepatotoxicity group, CCl4-induced acute hepatotoxicity combined SHSST treatment group, CCl4-induced acute hepatotoxicity combined SHSSTc treatment group, CCl4-induced acute hepatotoxicity combined silymarin treatment group were calculated and shown. TC total cholesterol (mg/dL), TG triacylglycerol (mg/dL), AST aspartate transaminase (U/L), ALT alanine transaminase (U/L), BUN blood urea nitrogen (mg/dL), CK creatine kinase (U/L). ( *** = P <0.001 compared with control group, # = P <0.05 compared with CCl4-IP group, ## = P <0.01 compared with CCl4-IP group, ### = P <0.001 compared with CCl4-IP group)